LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.15, MarketWatch Earnings reports. LAVA Therapeutics had a negative return on equity of 67.23% and a negative net margin of 557.33%. The business had revenue of $0.05 million for the quarter.
LAVA Therapeutics Stock Performance
LVTX stock opened at $1.50 on Friday. The company has a current ratio of 5.31, a quick ratio of 5.31 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average price is $1.43 and its two-hundred day moving average price is $1.74. LAVA Therapeutics has a fifty-two week low of $1.13 and a fifty-two week high of $7.38.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its position in LAVA Therapeutics by 30.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 65,000 shares of the company’s stock worth $132,000 after buying an additional 15,000 shares during the period. Renaissance Technologies LLC bought a new position in LAVA Therapeutics during the 4th quarter worth $66,000. Bank of America Corp DE increased its position in LAVA Therapeutics by 20,566.7% during the 1st quarter. Bank of America Corp DE now owns 32,240 shares of the company’s stock worth $54,000 after buying an additional 32,084 shares during the period. Finally, Bruce & Co. Inc. bought a new position in LAVA Therapeutics during the 4th quarter worth $350,000.
Wall Street Analyst Weigh In
LAVA Therapeutics Company Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
- Five stocks we like better than LAVA Therapeutics
- Energy and Oil Stocks Explained
- MarketBeat Week in Review – 11/13 – 11/17
- Stock Market Sectors: What Are They and How Many Are There?
- 3 large caps with red hot RSIs with upside
- Video Game Stocks: How to Invest in Gaming
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.